SCYNEXIS to Present at the BIO Digital International Convention 2021
June 11, 2021 08:30 ET | Scynexis
Company presentation will highlight BREXAFEMME® (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital...
SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections
June 09, 2021 08:30 ET | Scynexis
BREXAFEMME to receive 5-year exclusivity extension under the GAIN Act for a total of 10 years of regulatory exclusivityBREXAFEMME also protected by composition-of-matter patent until 2035Commercial...
SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections
June 02, 2021 07:30 ET | Scynexis
Approval of BREXAFEMME (ibrexafungerp) represents the first approved drug in a novel antifungal class in more than 20 yearsBREXAFEMME, a one-day oral treatment for vaginal yeast infection, is the...
SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 08:30 ET | Scynexis
Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon...
SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank
May 14, 2021 08:30 ET | Scynexis
Together with SCYNEXIS’ $93M cash balance at 12/31/20, the non-dilutive capital injections from this term loan, the recent licensing payments from Hansoh Pharma, and the monetization of 2020 New...
SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch
May 11, 2021 08:30 ET | Scynexis
Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and...
SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
April 30, 2021 08:00 ET | Scynexis
A single-day dose of oral ibrexafungerp demonstrates positive clinical outcomes in difficult-to-treat vulvovaginal candidiasis (VVC) patient populations: those with non-albicans Candida VVC and/or...
SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting
April 20, 2021 08:00 ET | Scynexis
JERSEY CITY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021 08:20 ET | Scynexis
FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name BrexafemmeTM, and granted priority review...
SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
March 02, 2021 07:30 ET | Scynexis
Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal...